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OBJECTIVES We sought to evaluate the prognostic and cost implications of stress myocardial perfusion
single-photon emission computed tomography (SPECT), or MPS, in patients with a high
pretest likelihood (0.85) of coronary artery disease (CAD) with no previous CAD.
BACKGROUND Sparse data are available regarding the prognostic performance characteristics of MPS in this
patient group.
METHODS We followed up 1,270 consecutive patients with no previous revascularization or myocardial
infarction (MI), with a pre–exercise tolerance test (ETT) likelihood of CAD 0.85, who
underwent exercise or adenosine stress MPS (follow-up 94.4% complete; 2.2  1.2 years; 60
hard events [5.9%, 2.6%/year]). Risk adjustment of survival data was done using Cox
proportional hazards analysis. Costs per reclassification of risk were calculated using assumed
costs and threshold analyses.
RESULTS In patients treated medically after MPS, normal MPS had a low risk of cardiac death and hard
events (0.6% and 1.3% per year, respectively). With increasing extent and severity of MPS
defects, the risk of both cardiac death and hard events increased significantly (p  0.05). Cox
models indicated that the addition of MPS data resulted in incremental prognostic value over
pre-MPS data (chi-square increase 48 to 87, p 0.0001). Compared with strategies of initial
referral to ETT in patients able to exercise, initial referral to MPS appeared to be a more
cost-effective strategy. Similarly, compared with a strategy of direct referral to catheterization
in patients with a high likelihood of CAD, initial referral to MPS is a cost-saving approach.
CONCLUSIONS In patients with a high likelihood of CAD but without known CAD, stress MPS yields
incremental value and achieves risk stratification in a cost-effective manner. The current
results support a strategy of initial stress imaging in this patient cohort, as a reasonable
alternative to direct referral to catheterization or initial ETT. (J Am Coll Cardiol 2004;43:
200–8) © 2004 by the American College of Cardiology Foundation
In light of the staggering mortality, morbidity, and cost
associated with coronary artery disease (CAD) in the U.S.,
increasing demands have been placed on the medical com-
munity to enhance the efficiency of the valuation and care of
See page 209
patients with this disease. With respect to noninvasive
testing, there is increasing appreciation of the importance of
identifying which patients are appropriate for testing. Con-
sequently, testing algorithms and guidelines are continu-
ously being refined on the basis of new research.
Selection of appropriate patients for testing is the first
important step in the process of cost-effective risk stratifi-
cation. Traditionally, the use of noninvasive testing in
patients with suspected CAD has been defined in terms of
an anatomic end point and is guided by the principle that
the patient’s pretest likelihood of angiographically signifi-
cant CAD determines the best clinical approach (1). Using
this approach for diagnosis of the presence of anatomic
CAD, only patients with an intermediate likelihood of
CAD are considered candidates for exercise treadmill test-
ing, because in this range, the results would reclassify
patients as having either a low likelihood (not in need of
further testing) or a high likelihood (in need of angiography
to determine the suitability for revascularization). This
approach is embodied in multiple American College of
Cardiology/American Heart Association (ACC/AHA)
guidelines in which stress testing, with and without stress
imaging, is considered a class IIb indication (usefulness/
efficacy is less well established by evidence/opinion) for
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diagnostic testing in patients with either a high or low
pretest probability of CAD (2–5).
On the other hand, for the management of patients with
chronic stable angina (3), ACC/AHA/American College of
Physicians-American Society of Internal Medicine (ACP-
ASIM) guidelines acknowledge that stress myocardial per-
fusion single-photon emission computed tomography
(SPECT), or MPS, can provide clinically useful informa-
tion with respect to risk and prognosis in some patients with
a high pretest likelihood of CAD. To date, however,
guidelines suggest that this application would only achieve a
class I indication when stress testing without imaging
cannot be effective. Furthermore, it is not yet clear whether
these patients with a high likelihood of CAD can be
stratified into low- and high-risk subgroups by MPS results.
To date, studies investigating the prognostic value of MPS
in patients considered to have a high likelihood of CAD
predominantly include patients who actually have docu-
mented CAD (3,6–10), such as patients with a previous
myocardial infarction (MI) and/or revascularization. Also,
the subsets of reported “high-likelihood” patients with no
previous MI or revascularization are relatively small cohorts
(11–13). With this in mind, the current study considers a
larger cohort than those previously examined. We hypoth-
esize that the ability of a normal stress MPS image to
identify low-risk patients in a cohort of patients without
known CAD but with a high likelihood of CAD will result
in effective and clinically useful risk stratification in a
cost-effective manner.
METHODS
Study population. We identified 1,345 consecutive pa-
tients with a pre-exercise tolerance test (ETT) likelihood of
CAD (0.85), based on age, gender, symptoms, and CAD
risk factors (1), who underwent exercise or adenosine stress
dual-isotope SPECT between March 1991 and May 1998,
with no history of revascularization or MI. Of these pa-
tients, 75 (5.6%) were lost to follow-up, leaving 1,270
patients with follow-up performed at least one year after the
index SPECT study. Patients who were known to have
valvular heart disease or primary cardiomyopathy were not
considered for this study.
A 60-day time point after stress SPECT has been shown
to be a temporal threshold distinguishing referrals to revas-
cularization made on the basis of the scan results (60
days), as opposed to worsening of the patient’s clinical
status, prompting intervention (60 days) (14). For this
reason, 249 patients (19.6%) who underwent revasculariza-
tion within 60 days after their index SPECT study were also
excluded from the prognostic analyses but were included in
analyses of resource utilization.
Imaging and stress protocol. Patients were injected intra-
venously at rest with 2.5 to 3.5 mCi of thallium-201
(Tl-201) with dose variation, based on patient weight. Rest
Tl-201 imaging was initiated 10 min after injection of the
isotope (15).
EXERCISE STRESS PROTOCOL. Immediately after imaging,
patients performed a symptom-limited treadmill exercise
test, using standard protocols with 12-lead electrocardio-
graphic (ECG) recording each minute of exercise and
continuous monitoring of leads aVF, V1, and V5. Blood
pressure was measured and recorded at rest, at the end of
each exercise stage, and at peak exercise. Exercise end
points included physical exhaustion, severe angina, sus-
tained ventricular tachycardia, hemodynamically significant
supraventricular dysrhythmias, and significant exertional
hypotension. At near maximal exercise, a 20- to 30-mCi
dose of technetium-99m (Tc-99m) sestamibi was injected
(actual patient dose varied with patient weight), and exercise
continued for one additional minute after injection.
Technetium-99m sestamibi SPECT imaging was begun
30 min after isotope injection (15). The maximal degree of
ST-segment change at 80 ms after the J point of the ECG
was measured and assessed as horizontal, upsloping, or
downsloping. Resting ECGs were considered interpretable
for ETT if left bundle branch block, paced rhythm, or
Wolff-Parkinson-White syndrome was not present (16).
ADENOSINE MYOCARDIAL PERFUSION PROTOCOL. Patients
were instructed not to consume coffee or other products
containing caffeine for 24 h before the test. After rest
Tl-201 SPECT, pharmacologic stress was applied with an
adenosine infusion (140 g/kg/min for 6 min). Technetium-
99m sestamibi (20 to 30 mCi) was injected at the end of the
third minute of infusion, and SPECT was initiated 60
min after the end of the adenosine infusion (15). During
both types of stress, blood pressure was measured and
recorded at rest, at the end of each stress stage, and at peak
stress. The maximal degree of ST-segment change at 80 ms
after the J point of the ECG was measured and assessed as
horizontal, upsloping, or downsloping. For patients who
underwent exercise as an adjunct to adenosine infusion,
low-level treadmill exercise was performed at 0% grade and
1.0 to 1.7 mph.
The SPECT acquisition protocol. The SPECT studies
were performed as previously described, using a circular or
elliptical 180° acquisition for 64 projections at 20 s per
projection (15). During imaging, two energy windows were
utilized for Tl-201 (30% window centered on the 68- to
Abbreviations and Acronyms
CAD  coronary artery disease
ETT  exercise tolerance test
MI  myocardial infarction
MPS  myocardial perfusion SPECT
SPECT  single-photon emission computed tomography
SDS  summed difference score
SRS  summed rest score
SSS  summed stress score
Tc-99m  technetium-99m
Tl-201  thallium-201
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80-keV peak and 10% window centered on the 167-keV
peak), and a 15% window centered on the 140-keV peak
was used for Tc-99m sestamibi. No attenuation or scatter
correction was used.
Image interpretation. A semiquantitative visual interpre-
tation was performed using 20 segments for each rest and
stress image (15). Each segment was scored by the consen-
sus of two experienced observers using a 5-point scoring
system (0  normal; 1  equivocal; 2  moderate; 3 
severe reduction of radioisotope uptake; and 4  absence of
detectable tracer uptake in a segment), as previously
described.
Scintigraphic indexes. The summed stress score (SSS) was
obtained by adding the scores of the 20 segments of the
stress images (17). Summed stress scores 4 were consid-
ered normal; 4 to 8  mildly abnormal; and 8 
moderately to severely abnormal. A summed rest score
(SRS) was obtained by similarly adding the scores of the 20
segments of the rest thallium images. The sum of the
differences between each of the 20 segments on the stress
and rest images was defined as the summed difference score
(SDS), a variable representing the amount of ischemia
present. Each of these variables incorporates both the extent
and severity of perfusion defects, both of which indepen-
dently add prognostic information (18). Summed difference
scores 2 were considered as no ischemia; 2 to 4  mild
ischemia; 5 to 8  moderate ischemia; and 8  severe
ischemia.
Patient follow-up. Patient follow-up was performed by
scripted telephone interview by individuals blinded to the
patients’ test results. Hard events included both cardiac
death and nonfatal MI. The latter was said to have occurred
if a patient presented with signs and symptoms suggestive of
MI and enzyme elevations (creatine kinase-MB fraction or
lactic dehydrogenase), in addition to any of the following
conditions: 1) emergent treatment with percutaneous trans-
luminal coronary angioplasty or thrombolysis; 2) develop-
ment of new Q waves on the resting ECG in the setting of
either delayed or silent presentation, so that enzymatic
diagnosis was not possible; or 3) new Q waves or enzymatic
increase sufficient to diagnose perioperative MI. Cardiac
death was defined as death due to any cardiovascular cause,
as noted and confirmed by a review of the death certificate
and hospital chart or physician’s records. Patients undergo-
ing revascularization within 60 days after MPS were cen-
sored from all analyses, and subsequent events were not
considered unless specified. Patients undergoing revascular-
ization 60 days after MPS were considered in all analyses,
and events subsequent to this revascularization were con-
sidered in analyses. Patients included in this report were not
contacted until at least one year after their index SPECT
study.
Statistical analysis. Comparisons between patient groups
were performed using one-way analysis of variance with
Bonferroni correction, as appropriate, for continuous vari-
ables and the chi-square test for categorical variables. All
continuous variables are described as the mean value  SD.
A p value 0.05 was considered statistically significant.
Survival analysis. To determine the incremental prognos-
tic value of MPS, risk-adjusted, multivariate survival anal-
ysis was performed with a Cox proportional hazards model
(19) in a stepwise fashion, using S-plus 2000 (Mathsoft,
Cambridge, Massachusetts). Incremental prognostic value
was assessed by first considering prescan information in an
initial model and forcing it into the model before consid-
ering MPS data. The primary end point for all models was
the occurrence of hard events. Secondary analyses of cardiac
death and all-cause death were also performed. A statisti-
cally significant increase in the global chi-square value of the
model after the addition of nuclear variables defined incre-
mental prognostic value. The threshold for entry of variables
into all models was p  0.05, and the threshold for removal
of variables was p  0.10. Based on these models, risk-
adjusted survival curves were determined. Assumptions of
proportional hazards, linearity, and additivity were exam-
ined (20,21).
Logistic regression. Logistic regression was performed
using S-plus 2000. Assumptions of linearity and additivity
were examined (20,21). The threshold for entry of variables
into all models was p  0.05, and the threshold for removal
of variables was p  0.10. This type of modeling was used
in cost analyses to determine one-year predicted risk and in
resource utilization analyses to determine the most predic-
tive model of referral to revascularization. The c index is
reported as a measure of model robustness, and bootstrap
analyses (80 iterations) were employed, as appropriate.
Cost analysis. The cost implications of MPS in patients
after ETT was performed were calculated by determining
the number of patients who were reclassified with respect to
their risk of adverse outcomes by the addition of MPS data
to prescan information (high vs. low risk after ETT as
defined by a logistic model of hard events; reclassification
based on a logistic model incorporating MPS data)
(3,22,23). Correct reclassification was defined as: 1) a
post-MPS risk 1% in patients at 1% risk by ETT who
had no event; or 2) a post-MPS risk 1% in patients at
1% risk by ETT who had an event on follow-up. Incorrect
reclassification was defined as: 1) a post-MPS risk 1% in
patients at 1% risk by ETT who had an event on
follow-up; or 2) a post-MPS risk 1% in patients at 1%
risk by ETT who had no event on follow-up. The net
change in reclassifications with MPS results was defined as
the number of correct reclassifications minus the number of
incorrect reclassifications. Costs per reclassification of risk
were calculated as noted earlier. The cost of MPS used for
all cost analyses was $840 and that of catheterization
$2,800, as in previous studies, to permit direct comparisons
with previous work (24). Threshold analyses were per-
formed to compare the relative cost effectiveness of MPS
and catheterization. The comparison between costs with
MPS and costs with direct referral to catheterization was
made with respect to the cost per hard event detected,
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factoring in the costs of MPS and catheterization, as noted
earlier.
Resource utilization. Analyses of resource utilization em-
ployed referral to catheterization and revascularization
within 60 days after the index SPECT study as the end
points of interest.
Quantifying the impact of early revascularization on
observed event rates. Based on the variables presented in
the aforementioned Cox proportional hazards model, logis-
tic regression analysis was performed also modeling hard
events in patients not undergoing early revascularization.
Using this model, the predicted probabilities for hard events
were then calculated for patients both with and without
early revascularization (20,21).
RESULTS
Patient characteristics. The pre-ETT likelihood of CAD
in the patients included in the current study was 0.94 
0.04. The characteristics of the patients in the study cohort
are shown in Table 1. Overall, the patients were middle-
aged to elderly, about half were women, and two-thirds
underwent exercise stress. With respect to cardiac risk
factors, about one-fifth of patients had diabetes mellitus or
had a history of smoking, one-quarter had a family history
of CAD, about half had hypertension or hypercholesterol-
emia, and 95% presented with typical angina. One-fifth of
patients had previous catheterization, and 94% had a resting
ECG interpretable for ETT. About one-fifth of patients
had ischemic ECG results on their stress studies. With
respect to MPS results, the average SSS was 5.5, with most
of the defects being reversible (SDS  4.8).
Outcome events. In the cohort of 1,021 patients used for
the prognostic analysis, over a mean follow-up of 2.2  1.2
Table 1. Patient Characteristics
Total
(N  1,021)
Hard Events
(n  60)
No Hard
Events
(n  961)
Age (yrs) 69  10 73  9 69  10*
Male gender 564 (55%) 37 (62%) 527 (55%)
History of catheterization 199 (19%) 19 (32%) 180 (19%)*
Diabetes mellitus 199 (19%) 18 (30%) 181 (19%)*
Hypertension 576 (56%) 34 (57%) 542 (56%)
Hypercholesterolemia 490 (48%) 28 (47%) 462 (48%)
Family history of CAD 246 (24%) 17 (28%) 229 (24%)
Smoking 149 (14%) 8 (13%) 141 (15%)
Typical angina 975 (95%) 52 (87%) 923 (96%)*
Rest ECG interpretable
for ETT
905 (94%) 53 (88%) 958 (94%)*
Ischemic stress ECG 220 (21%) 16 (27%) 204 (21%)
Exercise stress 637 (62%) 26 (43%) 611 (64%)*
SSS 5.5  8.0 12.0  9.9 5.1  7.7*
SRS 0.9  3.6 2.8  6.3 0.8  3.3*
SDS 4.8  6.8 9.2  8.2 4.3  6.7*
*p  0.05 vs. hard events. Data are presented as the mean value  SD or number (%)
of patients.
CAD  coronary artery disease; ECG  electrocardiogram; ETT  exercise
tolerance test; SDS  summed difference score; SRS  summed rest score; SSS 
summed stress score.
Table 2. Frequencies of ACD, CD, and HE Per Year as a
Function of the Stress Myocardial Perfusion Single-Photon
Emission Computed Tomographic Result
Normal
Mildly
Abnormal
Moderate to
Severely Abnormal
All patients
ACD 1.3% 2.7% 6.7%*
CD 0.6% 0.7% 3.3%*
HE 1.3% 1.8% 7.0%*
n 593 188 240
Exercise stress
ACD 0.8% 2.2% 3.5%*
CD 0.2% 0.0% 2.1%*
HE 0.8% 1.8% 5.4%*
n 395 104 138
Adenosine stress
ACD 2.5% 3.4% 10.6%*
CD 1.3% 1.4% 4.7%*
HE 2.3% 1.9% 8.9%*
n 198 84 102
*p  0.05 across myocardial perfusion single-photon emission computed tomography
result categories.
ACD  all-cause death; CD  cardiac death; HE  hard events; n  number of
patients within MPS result category.
Figure 1. Risk-adjusted survival curves based on Cox proportional hazards
analysis for patients undergoing exercise (A) and adenosine stress (B) as a
function of scan results: normal, mildly abnormal (Abnl), and moderate to
severely abnormal (Mod-Sev Abnl). p  0.001 for both, across categories
of scan results.
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years, 60 hard events occurred (28 cardiac deaths [1.2%
per year] and 32 MIs [5.9% hard event rate, 2.6% per
year]). In addition, 65 all-cause deaths occurred during
this period (6.4%, 2.8% per year). The subset of 384
patients who underwent pharmacologic stress experienced
34 hard events (3.9% per year), and of the 662 patients
who underwent exercise stress, 26 experienced hard events
(1.9% per year). Furthermore, 371 early catheterizations
(29.2%), 249 early revascularizations (19.6%), and 142 late
revascularizations occurred (“early” defined as within the
first 60 days after MPS; “late” as after the first 60 days after
MPS).
Univariate predictors of hard events. As shown in
Table 1, univariate predictors of hard events included age,
previous catheterization, diabetes mellitus, typical angina,
rest ECG interpretable for ETT, and use of pharmacologic
stress. In addition, both the extent and severity of stress and
rest and reversible defects were significant predictors of hard
events.
Perfusion scan abnormalities and hard events. The rela-
tionship between scan results and annualized frequencies of
all-cause death, cardiac death, and hard events for all
patients and patients undergoing exercise and adenosine
stress is shown in Table 2. In all patient groups, the annual
frequencies for each of these end points increased signifi-
cantly across scan categories, thus indicating successful risk
stratification in all groups toward all end points examined.
Survival analysis. Cox proportional hazards analysis was
performed using hard events, cardiac death, and all-cause
death as end points. After adjusting for prescan data (type of
stress, age, previous catheterization), the addition of MPS
data resulted in a significant increase in the global chi-
squared value (48 to 87, p  0.0001) for prediction of hard
events. Adenosine stress, increasing age, SRS, and SDS
were identified as the model most predictive of hard events
(p  0.0001, chi-square  87), with the analysis stratified
by SDS due to violation of the proportional hazards
assumption. Risk-adjusted survival curves based on this
model are shown for the subsets of patients undergoing
exercise and pharmacologic stress (Figs. 1A and 1B). For
both patient subsets, a statistically significant survival dif-
ference was present across MPS categories (p  0.0001),
even after adjusting for other confounding variables, again
indicative of incremental prognostic value. With respect to
both cardiac death and all-cause death, this same model was
predictive (chi-square  60 and 99, respectively; both p 
0.0001).
Referral rates to catheterization and revascularization
after SPECT. Rates of referral to catheterization and
revascularization early (60 days) after the index MPS
study are shown in Table 3. In the overall patient cohort, as
well as in the subsets of patients undergoing exercise and
pharmacologic stress, referral rates to catheterization and
revascularization were relatively low in the absence of
inducible ischemia, although these referral rates increased
significantly with increasing extent and severity of stress-
induced ischemia (p  0.001). In the setting of severe,
inducible ischemia, a statistically significant difference was
found in referral rates to early catheterization and revascu-
larization between pharmacologic and exercise stress, but no
such differences were present between the other SDS
categories or with respect to referral rates to early revascu-
larization. The proportion of patients referred to catheter-
ization who went on to revascularization also tended to
increase across SDS categories. Using logistic regression,
the model most predictive of referral to revascularization
included SDS, type of stress, patient gender, diabetes mellitus,
and ischemic ECG response to stress, with significant inter-
actions between SDS and type of stress, patient gender, and
diabetes mellitus, as well as between SDS and patient gender
(chi-square  239, c index  0.85, p  0.0001).
Table 3. Rates of Referral to Early Catheterization and Revascularization as a Function of the
Extent and Severity of Inducible Ischemia
None
(SDS 0–1)
Mild
(SDS 2–4)
Moderate
(SDS 5–8)
Severe
(SDS >8) Total
Overall
Early catheterization 3.0% 19.9% 36.5% 65.3%* 29.2%
Early revascularization 0.9% 6.0% 21.0% 49.8%* 19.6%
Revascularized‡ 31% 30% 57% 76% 67%
n 537 166 167 400 1,270
Pharmacologic stress
Early catheterization 4.3% 26.2% 37.0% 56.9%* 28.2%
Early revascularization 1.1% 6.6% 17.8% 39.4%* 16.0%
Revascularized‡ 25% 25% 48% 69% 57%
n 186 61 73 137 457
Exercise stress
Early catheterization 2.3% 16.2% 36.2% 69.6%*† 29.8%
Early revascularization 0.9% 5.7% 23.4% 55.1%*† 21.6%
Revascularized‡ 38% 35% 65% 79% 73%
n 351 105 94 263 813
*p  0.01 across categories of SDS. †p  0.01 within SDS category between exercise and pharmacologic stress. ‡Percentage of
patients who underwent catheterization who were referred to revascularization.
SDS  summed difference score.
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Cost effectiveness of stress perfusion imaging: ETT
versus MPS. The cost per reclassification for MPS after
initial risk classification by ETT was evaluated in a subset of
617 patients with ECGs interpretable for ETT who under-
went exercise stress. The risk of hard events occurring in the
first year of follow-up was modeled using logistic regression
analysis. The most predictive model of prescan data con-
sisted of the Duke treadmill score alone (p  0.003, c index
 0.74, bootstrap c index  0.72) and the model incorpo-
rating MPS data included SSS and age (p 0.0001, c index
 0.91, bootstrap c index  0.89). On the basis of the
prescan model, 275 patients (5 hard events) were identified
as 1% risk and 342 patients (17 hard events) as 1% risk.
The results of the postscan model identified 49 of the
former as 1% risk, in whom three hard events occurred,
and 187 of the latter as 1% risk, in whom no events
occurred. Hence, 190 patients were correctly reclassified and
46 were incorrectly reclassified, for a net change of 144
reclassifications. Assuming a cost of $840 per MPS, this
resulted in a cost of $3,599 per reclassification, which
decreased to $2,999 for a cost of $700 per MPS and
increased to $3,856 for a cost of $900 per MPS.
Given the cost effectiveness of MPS in both the low- and
intermediate- to high-risk groups, as well as the risk in the
low prescan risk group (1.8% hard event rate in the first
year), it is possible that direct referral of patients with a high
pre-ETT likelihood of CAD to MPS rather than ETT
would be advantageous.
Cost effectiveness of stress perfusion imaging: MPS
versus catheterization. We compared two strategies in
patients with a high pre-ETT likelihood of CAD—direct
referral to catheterization versus referral to MPS with
subsequent referral to catheterization in patients with an
abnormal MPS image. Based on one-year follow-up in our
cohort of 1,021 patients, direct referral to catheterization
resulted in a cost of $95,293 per hard event detected
(assuming that all 30 hard events would be identified by
catheterization) versus $81,435 per hard event detected
(assuming all 1,021 patients had MPS and 428 had subse-
quent referrals to catheterization, with 26 hard events
detected). Threshold analysis revealed that assuming a cost
for catheterization of $2,800 initial MPS as a strategy
remained superior to referral to catheterization for all MPS
costs up to $1,200. Assuming a cost of $900 per MPS,
initial MPS as a strategy remained superior to referral to
catheterization for catheterization costs of $2,100 or higher.
Conversely, direct referral to catheterization is a superior
strategy to referral to MPS at costs below $2,100.
Impact of early revascularization on observed event
rates. Logistic regression analysis was performed using the
variables in the final Cox model described to model hard
events in patients not undergoing early revascularization (c
index 0.77, p 0.0001). In these patients, the observed and
predicted hard event rates were very similar (Table 4). Based
on this model, the hard event rate in patients undergoing
early revascularization would have been markedly greater
than those observed had no early revascularization been
performed (10.9% vs. 4.4%). Also based on this model, the
hard event rate in the overall study cohort, if no patients had
undergone early revascularization, would have been 19%
higher (5.9% vs. 4.8%).
DISCUSSION
The goals of the current study were to determine whether in
a cohort of patients with a high likelihood of but no known
CAD, MPS could identify patients at low risk of adverse
outcomes and achieve clinically applicable risk stratification
in a cost-effective manner. With respect to MPS, unad-
justed results indicated that MPS achieved excellent risk
stratification in the overall cohort, as well as in the sub-
groups that underwent exercise and adenosine stress. Nor-
mal MPS results were present in 47% of the overall
population of the current study (n  1,270) and in 58% of
patients who were treated medically (n  1,021). In the
latter, normal MPS was associated with low risk (cardiac
death rates of 0.6%/year, 0.2%/year, and 1.3%/year; hard
event rates of 1.3%/year, 0.8%/year, and 2.3%/year, in the
Table 4. Observed and Predicted Hard Event Rates in Patients With and Without
Revascularization After Stress Myocardial Perfusion Single-Photon Emission
Computed Tomography
SSS
TotalNormal
Mildly
Abnormal
Moderate to
Severely Abnormal
No early revascularization
Predicted 3.2% 5.6% 12.6% 5.9%
Observed 2.9% 4.3% 14.6% 5.9%
n 593 188 240 1,021
Early revascularization
Predicted* 3.7% 4.7% 10.9% 9.8%
Observed 0.0% 8.1% 4.4% 4.8%
n 8 37 204 249
*Predicted hard event rate based on model derived in patients with no early revascularization applied to patients with early
revascularization to estimate the number of events that would have occurred had revascularization not been performed. Predicted
hard event rates are those based on a logistic regression model derived in patients not undergoing early revascularization.
SSS  summed stress score.
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overall exercise stress and adenosine stress cohorts, respec-
tively). With worsening defect extent and severity, the
frequency of both cardiac death and hard events increased
significantly, particularly in the setting of moderate to
severely abnormal scans. Similar stratification was present
for all-cause death. Cox proportional hazards analyses
revealed that MPS results yielded incremental prognostic
value, even after adjusting for the most predictive pre-
SPECT data. With respect to cost effectiveness, MPS
appeared to be a superior strategy compared with initial
referral to ETT (in patients who are ETT candidates), as
well in the overall population of patients referred to MPS,
when compared with catheterization as an alternative strat-
egy. With respect to resource utilization, referral rates to
catheterization and revascularization increased in parallel to
increasing patient risk in all patient subgroups.
Previous studies. Although a number of previous studies
address the prognostic value of MPS in patients with a high
likelihood of CAD, these reports are dominated by reports
that include patients with a previous MI and/or revascular-
ization (3,6–10). Limited data exist regarding post-MPS
risk in patients without a previous MI and/or revasculariza-
tion with a high pretest likelihood of CAD. In first study
evaluating incremental prognostic value, we described (13) a
limited subset of patients with a high pre-ETT likelihood of
CAD (211 patients with normal and 35 patients with
abnormal rest ECGs), but this study utilized planar Tl-201
imaging. We have also previously shown in a cohort of
patients with no previous MI, revascularization, or cathe-
terization undergoing exercise stress, albeit a very small
cohort (n  79), that patients with a high pre-ETT
likelihood of CAD had no risk of hard events after normal
MPS and increasing risk with worsening MPS abnormali-
ties (3.3% and 15% hard event rates in patients with mildly
and moderate to severely abnormal scans, respectively) (12).
Of note, however, each of these previous studies was limited
with respect to the number of high-likelihood patients
included. With respect to observed hard event rates after
normal MPS, we have previously shown that the risk
associated with a normal MPS image, and its “warranty
period,” is adversely affected by increasing patient risk and
use of adenosine stress (25). However, this last study only
reported normal MPS; hence, no risk stratification could be
surmised. Therefore, the current study is the first to exam-
ine, with sufficient power, the ability of stress MPS results
to risk-stratify patients with a high likelihood of CAD, as
well as the cost implications of this approach.
Frequency of normal scans in patients with a high pretest
likelihood of CAD. In a cohort of patients with a high
likelihood of CAD (mean 0.94), it is expected that the vast
majority of patients would have abnormal scans. With this
prevalence, assuming a sensitivity of 90%, we would antic-
ipate that 85% of scans would have been abnormal. In the
current study, however, abnormal MPS occurred in only
53% of the overall cohort. This 32% difference can be
explained by several factors, including of the percent steno-
sis threshold used for defining CAD and post-MPS referral
bias in which patients with abnormal scans are preferentially
referred to catheterization.
Impact on clinical practice. As outlined in recent Be-
thesda Conference reports (26,27), a paradigm shift has
occurred in which the basis of patient evaluation has moved
from the likelihood of CAD to the risk of adverse events
secondary to CAD. As we have previously shown, test
performance characteristics of noninvasive imaging modal-
ities differ dramatically when anatomic and prognostic end
points are used (22). Thus, testing algorithms for the
evaluation of patients with suspected CAD might be altered
in a risk-based approach.
Although multiple current ACC/AHA guidelines define
stress testing, with and without stress imaging, as being a
class IIb indication for diagnostic testing in patients with
either a high or low pretest probability of CAD (2–5), the
ACC/AHA/ACP-ASIM guidelines for the management of
patients with chronic stable angina (3) indicate that in a
prognostic context, both exercise and stress imaging modal-
ities can provide clinically useful information on patient risk
and prognosis, which may be useful for determining patient
management. In the current study, we have shown that
although the subset of patients with interpretable rest
ECGs can be risk-stratified by exercise treadmill testing
without imaging, only a small proportion of these patients
are reclassified as sufficiently low risk so that no further
testing is required. Hence, exercise testing without imaging
in these patients is unlikely to be clinically efficient in
practice. The findings of the present study may be useful in
modifying current practice guidelines in this regard.
With respect to stress MPS, the results of the current
study support the use of the stress imaging modalities
described in the guidelines cited previously. In patients with
a high likelihood of CAD without a history of CAD, stress
MPS achieves excellent risk stratification, so that a majority
of patients are identified as low risk of future events.
Because sufficient numbers of patients are identified as low
risk, this approach achieves significant cost effectiveness
compared with a strategy of direct catheterization of these
patients. The current study also suggests that direct referral
to MPS is a superior strategy with respect to both cost and
identification of risk compared with a strategy of initial
referral to ETT.
Impact of early revascularization on observed event
rates. Prognostic studies commonly remove from analyses
those patients undergoing early revascularization, a proce-
dure known to reduce mortality in high-risk subsets of
patients. Because referral to catheterization and revascular-
ization rates increase as a function of the extent and severity
of inducible ischemia, patients expected to have the highest
event rates are excluded from prognostic analysis. The
observed event rates in patients with a high likelihood of
CAD will thus be expected to decrease with increasing
utilization of MPS results. As MPS results are increasingly
incorporated into clinical management, and patients more
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commonly receive intervention based on these results, in
observational studies evaluating the prognostic value, MPS
will appear to be less predictive, as the observed risk of
patients with abnormal scans will be reduced by these
revascularizations. We observed that the hard event rate in
patients undergoing early revascularization would have been
markedly greater than that observed had no early revascu-
larization been performed (10.9% vs. 4.4%), and the hard
event rate in the overall study cohort, if no patients had
undergone early revascularization, would have been 11%
higher (5.9% observed vs. 6.6% predicted).
Although this impact of referral to revascularization on
reducing the apparent prognostic strength of MPS has been
previously postulated (28,29), to our knowledge, the current
study represents the first time this phenomenon has been
quantified.
Study limitations. The principal limitation of the current
study is that the patients with a high likelihood of CAD
who we have examined are those preselected for stress MPS.
It is possible that these patients are not representative of
patients with a high likelihood of CAD referred directly to
catheterization. Furthermore, the patients in this study are
those referred to a university-affiliated community hospital
in a major urban area, limiting the degree to which the
results of this study should be generalized. The scintigraphic
studies in the current work were interpreted by experienced
observers using a standardized, semiquantitative approach
to visual interpretation, which we have developed and
documented to be highly reproducible (30,31). These form
the basis for existent quantitative analysis programs that
have been shown to correlate strongly with those of semi-
quantitative analysis (31).
Conclusions. In patients with a high likelihood of CAD
but without known CAD, stress MPS yields incremental
value and achieves risk stratification in a cost-effective
manner. The current results support a strategy of initial
stress imaging in this patient cohort as a reasonable alter-
native to direct referral to catheterization or initial ETT.
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